Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Several clinical studies have indicated that compared with intravenous (IV) administration, subcutaneous (SC) administration of Epoetin alfa may result in a dose-sparing effect in patients on hemodialysis. However, data also indicate wide inter-patient variability in response, with many patients requiring the same or a higher dose following conversion to SC administration. Convenience favors IV administration of Epoetin alfa in patients on hemodialysis, and patient preferences and comfort should also be primary considerations. For patients who prefer SC injections, the nurse's coordination of the required dosing, administration, and operational factors is key to maintaining and improving anemia-related outcomes.
Holloway
Maggie
M
Department of Pediatrics, Division of Pediatric Nephrology, University of California, Los Angeles, USA.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D002755:Choice Behavior; D015400:Clinical Nursing Research; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007676:Kidney Failure, Chronic / Q000150:complications; D009730:Nursing Assessment; D010358:Patient Participation; D018579:Patient Selection; D011994:Recombinant Proteins; D006435:Renal Dialysis / Q000009:adverse effects / Q000451:nursing / Q000523:psychology; D012107:Research Design; D016896:Treatment Outcome
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa